Bladder Cancer Drugs Global Market Report 2022 – Yahoo Finance

Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International and Johnson & Johnson.
New York, March 16, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Bladder Cancer Drugs Global Market Report 2022" –

The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%.

The bladder cancer drugs market consists of sales of bladder cancer drugs.Bladder cancer is cancerous tissue that occurs on the lining of the bladder.

These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others.

The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.NMIBC (non-muscle invasive bladder cancer) is cancer that develops in the tissue that lines the bladder’s inner surface.

There is no involvement of the bladder muscle. The different applications include low-grade tumors, high-grade tumors and distributed through various channels such as hospital pharmacy, retail pharmacy, others.

North America is the largest region in the bladder cancer drugs market in 2021.Middle East is expected to be the fastest growing region in the forecast period.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The number of bladder cancer cases has been on the rise.Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer.

According to American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market.

Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market.Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power.

For instance, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the Center for Drug Research And Development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology.

The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow.For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program.

Though these three programs are used in expediting the approval of drugs, there subtle differences.Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs.

Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments.Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness.

A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion.The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors.

Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk posted in a Twitter thread on Monday advising followers to own “physical things” when inflation is high. In the tweet, Musk said “As a general principle, for those looking for advice from this thread, it is generally better to own physical things like a home or stock in companies you think make good products, than dollars when inflation is high. I still own & won’t sell my Bitcoin, Ethereum or Doge fwiw.” The biggest takeaway for some followers seems to ha
Alibaba (BABA) made a stunning rebound on Wednesday, closing 37%, its biggest one day gain since 2014. The move added about $80 billion to the Chinese e-commerce giant's market cap in one day.
Aggressive buying spurs speculation that Berkshire CEO Warren Buffett may ultimately want to purchase the entire energy company.
What happened Electric vehicle (EV) stocks are volatile by nature. Most EV companies aren't yet profitable, and much of investors' excitement is built on hope and potential. But recent volatility hasn't been driven by the underlying business or market potential.
(Bloomberg) — Defying their stock-market counterparts, Treasury traders aren’t buying Jerome Powell’s upbeat pronouncements on growth. In fact, in the aftermath of Wednesday’s policy decision, one bond-market indicator of economic hardship is flashing red for the first time since the darkest days of the pandemic.Most Read from BloombergPowerful Quake Off North Japan Kills 4, More Than 90 InjuredIn a Chilling Threat, Putin Vows to Rid Russia of ‘Traitors’Ukraine Update: U.S. House Set to Revoke
Great Hill Capital Chairman Thomas Hayes sits down with Yahoo Finance Live to talk about the surge in China's internet companies, China's past tech crackdowns, and the forecasts for Chinese stocks like Alibaba.
Fast-food chain Wendy's wants to do something that Chipotle has done but McDonald's has struggled with.
An economy challenged by inflation and a market preparing for interest rate hikes have been made worse by Russia's invasion of Ukraine and the turmoil and uncertainty that has caused. In uncertain times, it's hard to know where to turn, but a good place to start might be with one of the world's greatest investors, Warren Buffett, founder and CEO of Berkshire Hathaway. A look at where Buffett and Berkshire are investing their money could prove illuminating for many investors.
News from China, the Russia-Ukraine war and the Federal Reserve spurred a big market rally. But don't get too excited yet.
Shares of e-commerce and cloud-computing behemoth Amazon (AMZN) have been volatile as of late, following news that the stock is getting a 20-for-1 split. That's a huge deal that will open the door to a new world of small retail investors. Indeed, splits for big tech has been some sort of trend lately, and Amazon is jumping aboard the bandwagon. Amazon's Split and Share Repurchase Ignite a Bounce Although splits are ultimately good for retail investors, they don't add value for existing sharehold
Right now, markets are facing a variety of headline headwinds, with more building up beyond the horizon. The current obstacles are well known: inflation is high, the Russo-Ukraine war, and the Western sanctions on Russia, promise to wreak havoc on international finance and commodities networks, and the US Federal Reserve is expected to start hiking interest rate this week. As if all that weren’t enough, it’s a midterm election year. Both the Democrats and Republicans are maneuvering to find adva
DEEP DIVE Investors don’t need to be told that stocks have been volatile. There’s a market of extremes as Russia’s war in Ukraine continues and investors wait to see what the Federal Open Market Committee does with interest-rate policy March 16.
India is preparing to buy heavily discounted crude oil from its long-time ally Russia. While this may not be much, a discount on Russian crude will surely lower India’s import bill, The Times of India reported today (March 16). Every 10% increase in crude oil prices would lead to a 0.3 percentage point-widening in India’s current account deficit (CAD), and in turn, a weaker rupee, Nomura Research said in a report recently.
SoFi's acquisition of Technisys could reap long-term benefits as the company continues building a best-in-class tech stack.
The Federal Reserve is expected today to raise short-term interest rates by 0.25%, marking the central bank's first substantial move to quell high inflation as prices rise at paces not seen in about 40 years.
The Federal Reserve will raise rates. Do you know how to trade the S&P 500 and Nasdaq afterwards? Here are the key levels to know now.
Japanese accountant Masamitsu has not travelled or gone to the cinema in years and rarely eats out. Instead, his annual salary of about $34,000 goes to support his family and has risen by just $4 a year for nearly a decade. Masamitsu's plight mirrors that of many workers at small and medium-sized firms in Japan, where the average salary in 2020 was $38,515, little changed from the 1990s and well below the average of $49,165 in countries of the Organisation for Economic Cooperation and Development (OECD).
Rivian investors have been bullish over the past two days, but there's much more work to be done.
Shares of digital payments and fintech giant Block (NYSE: SQ), formerly known as Square, rallied 8.2% higher today as of 1:15 p.m. ET. Tech stocks in general were rallying ahead of the U.S. Federal Reserve's hotly anticipated announcement on its benchmark interest rate. The NASDAQ Composite was up 2.2%.
Fortunately, there is a way around the Roth IRA roadblock for affluent taxpayers: a backdoor Roth IRA. For 2022, Roth IRA contributions are not allowed for single filers with a modified adjusted gross income (MAGI) of $144,000 or more or married couples filing jointly whose MAGI exceeds $214,000. Traditional IRAs, on the other hand, have no income limits for eligibility.


Add a Comment

Your email address will not be published. Required fields are marked *